Increased expression of HER2 is detected in 25–30% of breast cancers and is associated with poorly differentiated tumors with a high proliferative rate, positive axially lymph nodes and decreased expression of estrogen and progesterone receptors [3]. Here, ERBB2 is linked to breast carcinoma.